Clinical Trial Update: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating obinutuzumab in combination with high-dose ibrutinib for chronic lymphocytic leukemia patients with progression on single-agent ibrut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Michael Choi | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: WITHDRAWN